# US 2023/0067261 A1 · Methods for treating inflammatory conditions of the lungs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067261 A1
- Document ID: US20230067261A1
- Status: Published application
- Kind: A1
- Application number: 17/861,912
- Filed: 2022-07-11
- Published: 2023-03-02
- Earliest claimed: 2016-12-13
- Assignees: Defensin Therapeutics ApS
- Applicants: Defensin Therapeutics ApS
- Inventors: Peter Nordkild; Søren Kjærulff
- Web page: https://patentgrep.com/patent/US20230067261A1

## CPC

- A61K 38/1729: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 38/38: Albumins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian α- and/or β-defensin.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method of treatment of asthma, bronchiectasis, chronic obstructive pulmonary disorder (COPD) or emphysema, the method comprising oral or intrapulmonary administration of at least one defensin selected from the group consisting of HD5, HD6, hBD1, hBD2, hBD3, hBD4, and hBD2 N-terminally truncated by 1-4 amino acids to a subject in need thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein said asthma is mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, or status asthmaticus.

### Claim 31 (depends on 29)

The method of claim 29, wherein said asthma is steroid refractory.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the administration is oral.

### Claim 33 (depends on 29)

The method according to claim 29, wherein said defensin is hBD1, hBD2, hBD3, hBD4, or N-terminally truncated hBD2 by 1-4 amino acids.

### Claim 34 (depends on 29)

The method according to claim 29, wherein said defensin is hBD2 or hBD2 N-terminally truncated by 1-4 amino acids.

### Claim 35 (depends on 29)

The method according to claim 29, wherein at least two defensins are administered.

### Claim 36 (depends on 35)

The method according to claim 35, wherein said at least two defensins are hBD2 and HD5.

### Claim 37 (depends on 29)

The method according to claim 29, wherein said method increases pulmonary compliance, reduces airway hyper responsiveness, or increases peak expiratory flow in the subject.

### Claim 38 (depends on 29)

The method according to claim 29, wherein said method results in increasing gene richness, increasing the number of phylae, increasing butyrate production and/or tryptophan production, or decreasing acetate production of or from lung microbiota.

### Claim 39 (depends on 29)

The method according to claim 29, wherein the subject has
a. asthmatic symptoms more than 2 times per week;
b. asthmatic attacks at varying intensity;
c. asthmatic symptoms at night more than 2 times per month;
d. a forced expiratory volume at 1 second (FEV1) less than 80; or
e. a peak expiratory flow rate (PEFR) with a variability of more than 20%.

### Claim 40 (depends on 29)

The method according to claim 29, wherein the defensin is administered in combination with one or more glucocorticoids, β-agonists, leukotriene receptor antagonists, theophylline, antibiotics, rifaximin, immunosuppressants, chemo- or immune therapy, prebiotics, probiotics, tryptophane, fatty acids, HNP-1, HNP-2, HNP-3, HNP-4, cathelicidin, lactoferrin, lactoferricin, lysozyme, fecal transplants or any combination thereof.

### Claim 41 (depends on 29)

The method according to claim 29, wherein said defensin is administered at a dosage of 0.1 mg to 10 mg defensin/kg per day.

### Claim 42 (depends on 29)

The method according to claim 29, wherein said defensin is administered every other day.

### Claim 43 (depends on 29)

The method according to claim 29, wherein said defensin is administered daily.

### Claim 44 (depends on 29)

The method according to claim 29, wherein the treatment alleviates at least one continuous asthmatic symptom.

### Claim 45 (depends on 29)

The method according to claim 29, wherein said intrapulmonary administration is intratracheal, intrabronchial, or bronchio-alveolar.

### Claim 46

A method of treatment of steroid refractory asthma, the method comprising oral administration of hBD2 to a subject in need thereof.

### Claim 47

A method of treatment of COPD, the method comprising oral administration of hBD2 to a subject in need thereof.
